<DOC>
	<DOC>NCT00882999</DOC>
	<brief_summary>To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.</brief_summary>
	<brief_title>A Study of Patients With Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>18 through 64 years of age diagnosed with relapsingremitting multiple sclerosis (RRMS), who can walk without aid or rest for at least 200 meters (approximately 1/10 of a mile). Women who can become pregnant must use birth control. Have had a live vaccination within 12 weeks before randomization, or intend to have a live vaccination during the course of the study. Have had had recent surgery or are scheduled to have surgery during the study. Are immunocompromised or have evidence of active infection (such as hepatitis, tuberculosis or, human immunodeficiency virus [HIV]). Have been on certain drugs that are being studied for RRMS or have recently received prescription drugs to treat RRMS. Have had a recent serious infection. Have serious or uncontrolled illnesses other than RRMS. Have clinically significant blood test values. Have multiple or severe drug allergies. Have contraindications for magnetic resonance imaging (MRI; "scanning") or claustrophobia (fear of an enclosed space) that cannot be managed.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Relapsing</keyword>
	<keyword>Remitting</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Multiple</keyword>
	<keyword>Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>LY2127399</keyword>
</DOC>